Such pitfalls may serve as an initial disadvantage that can be turned in an opportunity, since new conditions (especially nonprostatic tumors) can be imaged and perhaps in the future might even be considered for PSMA ligand radiopharmaceuticals in a theranostic approach, which is increasingly being used for PCa [71]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.